Following in Medicare Part Ds footsteps, commercial insurers have traditionally covered GLP-1s only for Type 2 diabetes diagnoses, while largely denying coverage for weight loss
What is still being studied Open scientific questions Long-term safety beyond the trial duration, weight regain after discontinuation, comparative effectiveness against Tirzepatide head-to-head, and response variability across populations are all areas where evidence is still maturing
Visceral fat is metabolically active and releases inflammatory signals that influence insulin resistance and cardiovascular risk
Scientists are now investigating GLP-1s potential effectiveness against alcohol use disorder, opioid addiction, and nicotine dependence
Mirroring data from sAC / mice, depletion of sAC in human caSMCs through a siRNA also abrogated cAMP responses to GLP-1(2836) (Figure 2I), providing further evidence of a nonreceptor, sAC-dependent mechanism
The elimination of needles and refrigeration often translates into better long-term persistence with Rybelsus compared to weekly injectable regimens
